title: Tumor stromal phenotypes define VEGF sensitivity--response.
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom. neil.n.r.smith@astrazeneca.com simon.t.barry@astrazeneca.com.
authors.forename: Neil R
authors.initials: NR
authors.lastname: Smith
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
authors.forename: Dawn
authors.initials: D
authors.lastname: Baker
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
authors.forename: Matthew
authors.initials: M
authors.lastname: Farren
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
authors.forename: Aurelien
authors.initials: A
authors.lastname: Pommier
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
authors.forename: Ruth
authors.initials: R
authors.lastname: Swann
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
authors.forename: Sunita
authors.initials: S
authors.lastname: Mistry
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
authors.forename: Karen
authors.initials: K
authors.lastname: McDaid
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
authors.forename: Jane
authors.initials: J
authors.lastname: Kendrew
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
authors.forename: Chris
authors.initials: C
authors.lastname: Womack
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom. Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Wedge
authors.affiliation: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom. neil.n.r.smith@astrazeneca.com simon.t.barry@astrazeneca.com.
authors.forename: Simon T
authors.initials: ST
authors.lastname: Barry
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D017154:Stromal Cells / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A